Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
The Lancet. Haematology|May 21, 2022
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b studyFrancesco Passamonti, Francesca Palandri, Guray Saydam, et al.
British Journal of Haematology|April 1, 2020
TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countriesAnna Turkina, Jianxiang Wang, Vikram Mathews, et al.
The Lancet. Oncology|December 6, 2016
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b studyFrancesco Passamonti, Martin Griesshammer, Francesca Palandri, et al.
Annals of Hematology|May 28, 2018
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trialMartin Griesshammer, Guray Saydam, Francesca Palandri, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 27, 2025
Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert PanelMeral Beksaç, Esra Sahli, Ahmed Rabea, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 4, 2013
STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cellsHatice Demet Kiper, Burcin Tezcanli Kaymaz, Aysun Adan Gokbulut, et al.
Annals of Hematology|February 4, 2018
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studiesJean-Jacques Kiladjian, Paola Guglielmelli, Martin Griesshammer, et al.
American Journal of Blood Research|July 15, 2015
Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuriaFahri Sahin, Melda Comert Ozkan, Nihal Gokmen Mete, et al.
Nutrition and Cancer|May 24, 2022
<i>Origanum Sipyleum</i> Methanol Extract in Combination with Ponatinib Shows Synergistic anti-Leukemic Activities on Chronic Myeloid Leukemia CellsCagla Kayabasi, Sunde Yilmaz Susluer, Tugce Balci Okcanoglu, et al.
Medical Oncology (Northwood, London, England)|January 21, 2022
Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysisCagla Kayabasi, Ayse Caner, Sunde Yilmaz Susluer, et al.
Pageof 8